<DOC>
	<DOC>NCT01758965</DOC>
	<brief_summary>The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors</brief_summary>
	<brief_title>Surgicel® Fibrillar for Delayed Bleeding After ESD</brief_title>
	<detailed_description>1. Patient (1) Inclusion: Diagnosed as gastric dysplasia or early gastric cancer - Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia - Anti-platelet agents 2. Method (1) Study group: combination with Surgicel® Fibrillar and H2RA (2) Control group: monotherapy with PPI 3. Sample size : 157 4. Result 1. Primary endpoint: rate of delayed bleeding after ESD 2. Secondary endpoint: follow-up hemoglobin after ESD</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>ESD for gastric dysplasia or early gastric cancer Coagulopathy: liver cirrhosis, thrombocytopenia Antiplatelet agents</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>